Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094685 · ClinicalTrials.gov registry record · Phase 2
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
A Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Resectable Head and Neck Squamous Cell Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT07094685 is a Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Resectable Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 28 participants, below the 35-participant average among 5 other Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07094685, a Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Resectable Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Biopsy Procedure
- BIOLOGICAL Ivonescimab
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2030-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07094685
The ClinicalTrials.gov registry entry for NCT07094685 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 5 other Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (20% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07094685 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07094685 about?
NCT07094685 is a clinical study titled "Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer". This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispeci...
What is the current status of trial NCT07094685?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-11-18. Estimated completion is 2030-11-01.
What conditions does trial NCT07094685 study?
This clinical trial studies the following conditions: Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT07094685?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Biopsy Procedure (PROCEDURE), Ivonescimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07094685?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07094685 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
COMPLETED · Phase 2
-
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
COMPLETED · Phase 2
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Resectable Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.